Deutsche Bank AG Acquires 74,275 Shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)

Deutsche Bank AG raised its stake in shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Free Report) by 93.8% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 153,441 shares of the company's stock after buying an additional 74,275 shares during the period. Deutsche Bank AG owned about 0.40% of Tarsus Pharmaceuticals worth $8,496,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also modified their holdings of TARS. Jennison Associates LLC raised its position in Tarsus Pharmaceuticals by 14.8% during the fourth quarter. Jennison Associates LLC now owns 2,500,132 shares of the company's stock valued at $138,432,000 after acquiring an additional 321,552 shares in the last quarter. Vanguard Group Inc. raised its holdings in Tarsus Pharmaceuticals by 0.9% during the fourth quarter. Vanguard Group Inc. now owns 2,115,162 shares of the company's stock valued at $117,117,000 after buying an additional 17,839 shares in the last quarter. Lord Abbett & CO. LLC lifted its position in shares of Tarsus Pharmaceuticals by 115.2% in the fourth quarter. Lord Abbett & CO. LLC now owns 1,279,987 shares of the company's stock worth $70,873,000 after buying an additional 685,111 shares during the last quarter. Invesco Ltd. boosted its stake in shares of Tarsus Pharmaceuticals by 36.7% during the 4th quarter. Invesco Ltd. now owns 932,115 shares of the company's stock worth $51,611,000 after acquiring an additional 250,018 shares in the last quarter. Finally, Geode Capital Management LLC increased its holdings in shares of Tarsus Pharmaceuticals by 0.4% during the 4th quarter. Geode Capital Management LLC now owns 838,804 shares of the company's stock valued at $46,456,000 after acquiring an additional 3,014 shares during the last quarter. 90.01% of the stock is currently owned by hedge funds and other institutional investors.

Tarsus Pharmaceuticals Stock Performance

Tarsus Pharmaceuticals stock traded up $0.15 on Thursday, hitting $43.34. The company's stock had a trading volume of 36,338 shares, compared to its average volume of 697,232. Tarsus Pharmaceuticals, Inc. has a one year low of $20.08 and a one year high of $57.28. The firm has a market cap of $1.82 billion, a P/E ratio of -11.34 and a beta of 0.94. The company has a quick ratio of 5.38, a current ratio of 5.42 and a debt-to-equity ratio of 0.30. The company has a fifty day moving average price of $47.88 and a 200-day moving average price of $49.15.

Tarsus Pharmaceuticals (NASDAQ:TARS - Get Free Report) last posted its earnings results on Thursday, May 1st. The company reported ($0.64) EPS for the quarter, topping the consensus estimate of ($0.69) by $0.05. Tarsus Pharmaceuticals had a negative return on equity of 55.86% and a negative net margin of 103.64%. The business had revenue of $78.34 million during the quarter, compared to the consensus estimate of $72.50 million. On average, equities analysts anticipate that Tarsus Pharmaceuticals, Inc. will post -3.17 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several equities research analysts recently weighed in on TARS shares. Guggenheim boosted their target price on Tarsus Pharmaceuticals from $78.00 to $84.00 and gave the stock a "buy" rating in a report on Friday, May 2nd. Oppenheimer upped their price objective on shares of Tarsus Pharmaceuticals from $65.00 to $72.00 and gave the stock an "outperform" rating in a report on Wednesday, January 22nd. Barclays dropped their target price on shares of Tarsus Pharmaceuticals from $62.00 to $60.00 and set an "overweight" rating on the stock in a report on Wednesday, February 26th. HC Wainwright reaffirmed a "buy" rating and issued a $73.00 target price on shares of Tarsus Pharmaceuticals in a report on Wednesday, February 26th. Finally, The Goldman Sachs Group upped their price target on Tarsus Pharmaceuticals from $46.00 to $51.00 and gave the stock a "neutral" rating in a report on Monday, May 5th. Two investment analysts have rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $66.33.

Insider Activity

In related news, General Counsel Bryan Wahl sold 3,341 shares of Tarsus Pharmaceuticals stock in a transaction dated Tuesday, March 18th. The shares were sold at an average price of $46.29, for a total transaction of $154,654.89. Following the completion of the transaction, the general counsel now directly owns 58,057 shares of the company's stock, valued at $2,687,458.53. This trade represents a 5.44% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Dianne C. Whitfield sold 2,315 shares of the company's stock in a transaction dated Tuesday, March 18th. The stock was sold at an average price of $46.29, for a total transaction of $107,161.35. Following the sale, the insider now directly owns 50,751 shares in the company, valued at $2,349,263.79. This represents a 4.36% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders have sold 32,542 shares of company stock worth $1,581,173. Corporate insiders own 8.25% of the company's stock.

Tarsus Pharmaceuticals Profile

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.